


# BeiGene Product Portfolio and Pipeline

Three marketed products in China, three late-stage assets, seven early-stage clinical assets



As of 8/13/19

	ASSETS	PROGRAMS	DOSE ESC.		DOSE EXPANSION		PIVOTAL		FILED	COMMERCIAL RIGHTS
			PH1a		PH1b	PH2*	PH2**	PH3		
Internally Developed	zanubrutinib (BTK)	monotherapy	R/R MCL, R/R CLL/SLL (NDAs accepted)							
			R/R WM							
		+ GAZYVA® (CD20)	WM, 1L CLL/SLL, R/R CLL/SLL							
			R/R MZL							
	tislelizumab (PD-1)	monotherapy	R/R FL							
			R/R cHL, 2L+ UC (NDAs accepted)							
		2L NSCLC, 1L HCC, 2L ESCC								
		2L/3L HCC								
		R/R NK/T-cell lymphoma								
		1L Sq. NSCLC, 1L Non-Sq. NSCLC, 1L NPC, 1L SCLC								
pamiparib (PARP)	monotherapy	1L GC, 1L ESCC								
		Solid tumors								
	+ TMZ (chemo)	B-cell malignancies								
		1L platinum-sensitive GC maintenance								
+ RT/TMZ (RT/chemo)	2L platinum-sensitive OC maintenance									
	3L gBRCA+ OC									
lifirafenib (RAF Dimer)	monotherapy	Solid tumors								
		B-Raf- or K-RAS/N-RAS-mutated solid tumors								
BGB-A333 (PD-L1)	monotherapy & + tislelizumab	B-Raf- or K-RAS/N-RAS-mutated solid tumors								
		Solid tumors								
BGB-A425 (TIM-3)	monotherapy & + tislelizumab	Solid tumors								
		Solid tumors								
Collaborations	REVLIMID®	(IMiD)	R/R MM (marketed), NDM (marketed), R/R NHL (Ph3)							
	ABRAXANE®	(albumin-bound paclitaxel)	Breast cancer (marketed), Metastatic pancreatic cancer (filed)							
	VIDAZA®	(hypomethylating agent)	MDS, AML with 20-30% bone marrow blasts, CMML (marketed)							
	sitravatinib	(multi-kinase inhibitor) <sup>1</sup>	NSCLC, RCC, OC, Melanoma, HCC/GEJ							
	ZW25	(bispecific HER2 antibody) <sup>2</sup>	Planned (in Ph2 ex-China by Zymeworks)							
	ZW49	(bispecific anti-HER2 ADC) <sup>2</sup>	Planned (in Ph1 ex-China by Zymeworks)							
	avadomide	(CC-122, CELMoD)	Planned (in Ph1b ex-China by Celgene)							
				China						

\*Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. \*\*Confirmatory clinical trials post approval are required for accelerated approvals. \*\*\*REVLIMID® approved as a combination therapy with dexamethasone. 1.Collaboration with Mirati Therapeutics, Inc; APAC study; 2. Collaboration with Zymeworks